Why BGPT?
logo

Check Claims Before You Publish

See how your reported results read as versioned evidence records — linked to experiments and limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review claims



    Explore by Goal












     Quick Explanation


    Wiebke Hülsemann — evidence-based scientific critique (bio/clinical limb development & surgery)
    From the information you provided (incl. OpenAlex snapshots), the author’s publication record appears clinically oriented with measurable citation impact; however, the provided evidence does not fully let me verify study design quality, reproducibility, or methodological rigor for each work.
    Key high-impact genetic/limb-malformation items include doi:10.1038/s41586-022-05682-1 and additional limb-genetics studies such as doi:10.1038/gim.2017.154 and doi:10.1111/cge.12352.



     Long Explanation


    Author Review: Wiebke Hülsemann
    Date: April 21, 2026 • Scope: scientific/biological strength, not social claims.
    1) What we can and cannot verify from the provided input
    • Can verify (with DOI-citable papers): existence/titles and (for some) the topical framing of selected works via DOI links (e.g., limb malformations genetics and related reviews).
    • Cannot fully verify (missing full text / methods): sample sizes, statistical methods, blinding/randomization, confounder handling, and reproducibility details for most works.
    • Important epistemic point: citation counts can reflect influence but are not a direct measurement of causal accuracy or methodological quality; they can be driven by field size, clinical urgency, and citation practices.
    2) Citation & productivity signals (from provided OpenAlex snapshot)
    Note: the following numeric summaries come from your provided OpenAlex snapshot (not from a DOI source). I use them only to visualize trends; for scientific conclusions I rely on DOI-citable content where available.
    3) Research areas inferred from works (top concepts / topics in snapshot)
    4) DOI-evidenced work themes (what appears scientifically “centered”)
    The provided top works show a mix of (i) congenital limb malformation genetics and (ii) clinical/orthopedic/plastic surgery topics.
    5) Scientific strength assessment (skeptical, evidence-weighted)
    5.1 What looks strong
    • Domain relevance and coherence: multiple provided DOI items cluster around congenital limb malformation genetics and related enhancer/CNV mechanisms, suggesting at least a consistent scholarly focus rather than superficial scatter. (This inference is based on the DOI list you provided; detailed verification would require inspecting each paper’s methods and citations.)
    • Engagement with mechanism-oriented genomics: the presence of a Nature-level mechanistic genomics paper indicates participation in high-bar genomic/functional interpretation contexts, at least at the contribution level.
    • Use of family-based genomic mapping: array CGH and enhancer/CNV association papers imply a clinical genetics workflow that typically uses patient cohorts and genotype–phenotype linkage.
    5.2 Skeptical red-flags & uncertainty
    • Review/clinical-report evidence is not automatically strong causal evidence: review articles and case-based clinical reports can be informative but do not establish causal mechanisms with the same rigor as well-powered, controlled genetic/experimental designs.
    • Potential genotype–phenotype association confounders: CNV/duplication studies can be affected by cohort ascertainment, reporting, and incomplete penetrance; without full methods, I cannot assess whether confounding and multiple testing were properly controlled.
    • Reproducibility gap in the provided material: I only see DOI-level pointers, not full-text methods/results for most entries—so I cannot verify power calculations, validation steps, blinding/observer bias handling (when clinical outcomes are involved), or whether negative findings were reported.
    • Citation-count interpretation limits: citation rates can be shaped by field-wide attention. Without normalizing for publication year and co-author networks, citation totals alone can mislead.
    5.3 What would most improve confidence
    • Full-text access (or methods excerpts) for: cohort size justification, variant calling/CNV pipeline, validation strategy (e.g., orthogonal assays), and statistical testing.
    • For clinical outcome papers: design type (prospective/retrospective), outcome definitions, inter-rater reliability, and confounder control.
    • Clear contribution statements: whether the author’s role is leading analysis, clinical data acquisition, or study supervision—because contribution level affects how we interpret “scientific quality.”
    6) Quick comparison table (DOI-based items only)
    Below table restricts to examples where DOI is explicitly provided in your prompt.
    DOI Theme Evidence type (inferred from title/description) Evidential strength (within provided info)
    10.1038/s41586-022-05682-1 Functional genomics of rare genetic disease (IDRs/phase separation) Mechanistic genetics/functional interpretation (per abstract snippet) moderate
    10.1038/gim.2017.154 Noncoding CNVs & congenital limb malformation Genomic association (CNV cohort) moderate
    10.1111/cge.12352 ZRS enhancer duplications & syndromic polysyndactyly Genotype–phenotype association (copy-number/duplication) moderate
    10.1186/s13023-014-0108-6 SHFM1 genomic region mapping (array CGH, 134 families) CNV mapping + critical-region delimitation moderate
    10.1055/s-0042-100460 Radial polydactyly clinical presentation & outcomes Review weak
    10.1055/s-0029-1238282 Adverse effects after Octenisept irrigation (pediatrics) Clinical report / hypothesis about toxicity weak
    7) Bottom-line scientific judgment (confidence-stated)
    Most supported claim from provided evidence: the author’s visible works include credible, genetics-focused studies of congenital limb malformations involving CNVs/enhancer biology and (in at least one case) participation in mechanistic genomics at high-profile venues. Confidence level: moderate for topical coherence and for “types of evidence present,” low-to-moderate for methodological rigor and reproducibility because full-text methods are not included in your prompt.
    What would falsify/seriously weaken this assessment: if the key genetics studies lack robust validation, have weak statistical support, or if the author’s contributions are mostly editorial/clinical without analytic leadership in the genomics components.
    This is a methodological threat statement—not a claim about the papers—because those details are not provided.


    Feedback:    

    Updated: April 21, 2026

     BGPT Author Review


    Scientific Quality

    60%

    Based on the provided snapshot, the author shows clinically and genetics-relevant publication themes with nontrivial citation impact. The scientific strength appears moderate: genetics works suggest association/mapping relevance, including at least one Nature-level mechanistic genomics context. However, the prompt lacks full-text methods, validation/statistics details, and contribution-level information for most papers, preventing a rigorous assessment of rigor/reproducibility; some listed items are reviews or clinical reports, which lower causal-evidence weight.


    Communication Quality

    60%

    Communication quality cannot be directly assessed from the prompt’s metadata/title snippets alone. Titles and topic framing suggest specialization coherence, but there is no access to writing clarity, structure, or critical discussion. Clinical/review papers likely communicate in field-standard formats, but evidence is insufficient to score highly.


    Author Novelty

    50%

    Novelty can’t be established from metadata alone. The topic set (CNVs, enhancer ZRS, limb malformation genetics) is established biology; novelty would depend on specific discoveries, breakpoint resolution, new mechanisms, or robust computational/experimental contributions, which aren’t verifiable here.


    Scientific Rigor

    50%

    Moderate-to-uncertain rigor. Evidence includes family-based CNV mapping and enhancer association studies (often reasonably rigorous), but the prompt does not include validation pipelines, statistical methods, power calculations, or reproducibility checks. Review/clinical-report items further limit the ability to gauge rigorous experimentation.

     Analysis Wizard



    Creates year-wise and topic-wise summary charts from the provided snapshot; then fetches DOI-level metadata links you provided to organize an evidence-weighted table of papers and evidence types.



     Hypothesis Graveyard


    The strongest driver of limb malformation phenotypes in these studies is a single coding mutation not captured by the reported CNV/enhancer work; unlikely given multiple CNV/enhancer-focused DOIs in the provided list.


    Phenotype association is entirely driven by ascertainment bias with no biological signal; falsified if breakpoint-resolved enhancer/CNV studies show consistent functional mechanistic follow-ups (not confirmable from the prompt).

     Science Art


    Author Review: Wiebke Hülsemann Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending